As part of The Lancet Rheumatology’s special issue on public and patient involvement in rheumatology, in this month’s episode, Aisling talks to Professor Jon Lampa about his recent publication on the patient-reported outcomes from the NORD-STAR trial.

The 2023 NORD-STAR trial was the first randomised trial to compare three different biological DMARDs, all in combination with methotrexate with active conventional treatment in patients with early rheumatoid arthritis. The study showed that after 48 weeks remission rates were higher in two of the three (Certolizumab pegol, abatacept, but not tocilizumab) biological DMARDs compared to active conventional treatment and that while radiographic progression was low, it was similar between groups. Providing an interesting insight into the management of patients with newly diagnosed rheumatoid arthritis.

Patient-reported outcomes are vital for measuring health, quality of life and treatment impact directly from the patient perspective–and now the data on how these treatments impact patient-reported outcomes is here.
We also discuss the importance of reporting patient-reported outcomes in clinical trials, the benefits of including patients and people with lived experience in research and what the future of patient-reported outcome measures looks like.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00007-X/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this month’s episode we discuss childhood-onset Sjögren’s disease-a rare and under-researched rheumatic condition.

Lack of robust clinical and immunological characterisation of this condition alongside assessment of its impact on quality of life has significantly hampered progress in the delivery of high-quality research and evidence-based recommendations for care. There are currently no studies following up children and young people with childhood-onset Sjögren's disease as they move into adulthood and there remains a clear knowledge gap surrounding the natural course and long-term outcomes of childhood-onset Sjögren's disease.

Professor Coziana Cuirtin from the Centre for Adolescent Rheumatology at the University College London discusses the long-term outcomes of patients with childhood-onset Sjögren’s disease. We also discuss barriers and facilitators to recruiting these patients, the current management strategies available and what’s next for childhood-onset Sjögren’s disease research.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00283-8/fulltext

-----------------------------------------------

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

This months episode covers Hemophagocytic lymphohistiocytosis, or HLH, a rare, life-threatening disorder characterised by dysregulated immune activity resulting in systemic inflammation, tissue damage and multiorgan failure which affects both children and adults.
The annual prevalence of HLH in England is around 2 per million people in the adult population, with an overall 1-year survival rate of around 50% and similar rates have also been reported in other countries across the world. However, as most studies of HLH prevalence primarily focus on single nations and specific subpopulations, epidemiological data on global incidence and mortality rates are scarce.
Dr Fiona Pearce and Dr Rachel Tattersall discuss their recent publication in The Lancet Rheumatology which looked at mortality rates of HLH across Europe, we also discuss what manifestations clinicians should be looking out for and what’s next for HLH research.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00292-9/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

During this episode, Dr John Isaacs and Dr Josh Bennett from Newcastle University and the NIHR Newcastle Biomedical Research Centre, discuss sarcopenia - an age-related loss of muscle mass and strength. Sarcopenia is relatively common in rheumatoid arthritis, with a prevalence ranging from 4·5% to 44% of people with rheumatoid arthritis, depending on the definition of sarcopenia used. Rheumatoid sarcopenia increases the risk of fall, fractures, disability, and hospitalisation. Therefore, prevention and management is important, especially in older patients. We discuss the how and why sarcopenia arises and how it can be managed, as well as the recent publication of the RAMUS study, which looked at the skeletal muscle effects of JAK inhibitor tofacitinib in rheumatoid arthritis. The link to the Nature Rheumatology Review mentioned can also be found below.
RAMUS study: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00184-5/fulltext
Nature Rheumatology Review: https://www.nature.com/articles/s41584-023-00921-9

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

This month's episode covers Sjögren’s disease—an autoimmune condition that primarily affects areas of the body that produce fluids, such as tears and saliva. The cause of the disease isn’t understood. Currently there are no licensed drugs to treat the disease, but phase 2 clinical trials have reported encouraging results, and phase 3 trials are underway.

Dr Samuel Bitoun, from the University of Paris-Saclay and APHP, discusses how Sjögren’s disease is currently classified, the challenges of using such classification, and how AI and deep learning could potentially contribute to this area, which is the focus of his recent study published in The Lancet Rheumatology, which aimed to train a neural network model to perform focus score classification and identify new histological patterns associated with this disease.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00181-X/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode, we’re tackling a condition that affects over 374 million people worldwide—knee osteoarthritis (OA). As the most common site of OA, knee OA is a leading cause of disability and accounts for more than 12 million disability-adjusted life years globally. With prevalence rising steadily due to aging populations and increasing obesity rates, the burden of knee OA is projected to climb even further in the coming decades.

We speak with the lead author of a new study published in The Lancet Rheumatology, Dr Scott Uhlrich, from the University of Utah. The study offers fresh insights into the management of knee OA through personalised gait retraining. We’ll explore the study’s design, its clinical implications, and what the future might hold for patients with knee OA.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00151-1?dgcid=buzzsprout_icw_podcast_September_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode, we'll be discussing an issue that affects millions of people globally - low back pain. We will find out why the burden of low back pain is so high, why current management is so ineffective, what we can do from a research and care perspective to improve outcomes for patients, and whether prevention is the way forward.

We’ll also discuss a couple of papers that have been recently published in The Lancet Rheumatology looking at longer-term treatment options for low back pain, and how useful they are.

Read the Systematic Review:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00064-5/abstract?dgcid=buzzsprout_icw_podcast_August_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode Professor Vibeke Strand discusses polymyalgia rheumatica (or PMR), a common inflammatory rheumatic disease that significantly impairs patients’ quality of life, causing fatigue, pain, and physical disability, especially in relapsing cases that often require long-term glucocorticoid treatment. However, these treatments come with considerable side effects, and many patients do not respond to treatment.

We also cover her recent publication, which explores the patient reported outcomes of a trial using sarilumab, a monoclonal antibody targeting the inflammatory cytokine IL-6, which has now been approved for treatment of PMR in the USA.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv